Acute Liver Failure: Science and Practice March 30-31, 2020 cme.utsouthwestern.edu/rp2003b Register now to attend!

PURPOSE AND CONTENT

Acute liver failure (ALF) is a rare but devastating condition that arises from diverse etiologies, has a high mortality and requires high resource utilization including transplantation.

The Acute Liver Failure Study Group (ALFSG) has been funded by NIDDK since 1997 to collect detailed clinical data on more than 3,500 patients, and will be closing its registry and database permanently in 2019. It is an opportune time to take stock, consider where the field of study of ALF is going, what has been accomplished and to determine future directions of research in this unique syndrome. The audience would include basic scientists that work on liver injury and clinicians (hepatologists, surgeons) who care for these very ill patients.

This two-day program will provide a comprehensive understanding of all aspects of the pathogenesis and treatment of ALF including possible future therapies. The initial day of the meeting will be devoted to allowing investigators to present work pertaining to pathogenesis and disease mechanisms. The second day of the meeting will be devoted to reviewing aspects of disease management including evaluation, treatment and consideration of prognosis, liver transplantation and liver support devices.

EDUCATIONAL OBJECTIVES

Upon completion of this activity, participants should be able to:

- Describe the differences between liver injury from Acetaminophen (APAP) vs. other drugs.
- Restate the role of cytokines in relation to injury evolution.
- Explain basic factors that promote liver regeneration.
- Explain the concept of sterile inflammation.
- Discuss different mechanisms of liver injury and the role of genomics in susceptibility to acute liver failure.
- Describe the current state of genome wide association studies. Review current state of identification of single nucleotide polymorphisms (SNPs) for specific diseases/drug injuries
- Review the elements of the basic and advanced work-ups for ALF patients.
- Identify natural history, differences in presentation, and how etiology drives prognosis and transplant decisions.
- Describe the circulatory and neurological physiology of ALF.

 Register online at https://cme.utsouthwestern.edu/rp2003b

- Explain new understanding regarding hemostasis in ALF, management of kidney injury and hemostasis.
- Compare present treatment modalities and propose possible future management protocols.
- Contrast the differences in presentation and outcome of different etiologies.
- Relate how etiology drives prognosis and transplant decisions.
- Envision novel approaches to managing ALF in the future.
- Describe current issues surrounding liver support devices.

TARGET AUDIENCE

This course is designed for providers in the specialties of Gastroenterology and Hepatology, Internal Medicine, Anesthesiology, Critical Care Medicine, and Surgery.

SPONSORED BY

UT Southwestern Department of Internal Medicine, Division of Digestive & Liver Diseases and the Office of Continuing Medical Education

ACCREDITATION AND DESIGNATION STATEMENT

The University of Texas Southwestern Medical Center is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Texas Southwestern Medical Center designates this live activity for a maximum of 12.25 AMA PRA Category 1 Credit TM . Physicians should only claim credit commensurate with the extent of their participation in the activity.

This course/program is endorsed by AASLD. The Acute Liver Failure Study Group is pleased to have received the endorsement of the American Association for the Study of Liver Diseases (AASLD). Copyright © 2020 by the American Association for the Study Diseases.

All rights reserved.

DISCLAIMER

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of AASLD. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications,

UTSouthwesternMedical Center

Acute Liver Failure: Science and Practice

March 30-31, 2020

cme.utsouthwestern.edu/rp2003b

Register now to attend!

| Agenda MONDAY, MARCH 30,2020 | | |
|------------------------------|---|------------------------------------|
| TIME | TOPIC | SPEAKER |
| 7:00 a.m. 8:00 a.m. | Registration/Breakfast | |
| 8:00 a.m. 10:15 a.m. | Session 1: Acute Liver Failure: Overview and Mechanisms | Moderators: Brendan McGuire, M.D., |
| | of Liver Injury | William M. Lee, M.D. |
| | Welcome and Introduction | Brendan McGuire, M.D. |
| | Acute Liver Failure and ALFSG | William M. Lee, M.D. |
| | Patterns of Liver Injury | Neil Kaplowitz, M.D. |
| | Clinical Phenotypes of ALF | Raj Reddy, M.D. |
| | Histopathology of ALF | David Kleiner, M.D. |
| | SIRS and the Role of Infection in ALF | (TBD) |
| 10:15 a.m. 10:30 a.m. | Break | |
| 10:30 a.m. 12:30 p.m. | Session 2: Liver Regeneration and Response to Injury | Moderators: Sanjeev Gupta, M.D., |
| | | Michael Schilsky, M.D. |
| | Overview of Basic Regenerative Mechanisms | Sanjeev Gupta, M.D. |
| | Immunologic Basis of Liver Injury/Response | Mark McPhail, M.D. |
| | Plasma Cells and Injury in HBV ALF | Patrizia Farci, M.D. |
| | Bio-markers in ALF | Mike Schilsky, M.D. |
| 12:30 a.m. 1:15 p.m. | Lunch | |
| 1:15 p.m. 2:45 p.m. | Session 3: Genomics of Liver Injury | Moderators: Raymond Chung, M.D., |
| | | Robert Fontana, M.D |
| | Genomics Overview | Raymond Chung, M.D. |
| | Genomics and Viral Liver Injury | Laurent Casanova, M.D.,PhD. |
| | Genomics of Drug-Induced Liver Injury | Paola Nicoletti, Ph.D. |
| 2:45 p.m. 3:00 p.m. | Break | |
| 3:00 p.m. 5:00 p.m. | Session 4: Diagnosis and Evaluation of ALF | Moderators: Jim Hanje, M.D., |
| | | Dan Ganger, M.D. |
| | Natural History of ALF | Ken Simpson, M.D. |
| | Workup of Acute Liver Failure: Checklist | Oren Fix, M.D. |
| | Case Presentation: New Diagnoses (HLH case) | Shannan Tujios, M.D. |
| | Causality: Determining Etiology in ALF | Daniel Ganger, M.D. |
| | | |



Acute Liver Failure: Science and Practice

March 30-31, 2020

cme.utsouthwestern.edu/rp2003b

Register now to attend!

| Agenda TUESDAY, MARCH 31,2020 | | |
|-------------------------------|---|-------------------------------------|
| TIME | TOPIC | SPEAKER |
| | | |
| 7:00 a.m. 8:00 a.m. | Registration/Breakfast | |
| 8:00 a.m. 9:30 a.m. | Session 5: Complications of ALF: Riding Out the Storm | Moderators: Dean Karvellas, M.D., |
| | | Jody Olson, M.D. |
| | Critical Care of ALF: Overview | Dean Karvellas, M.D. |
| | Hemostasis in ALF: Is There a Coagulopathy? | R. Todd Stravitz, M.D. |
| | Fluids, Pressors, Kidney Injury Management | Jody Olson, M.D. |
| 9:30 a.m. 9:45 a.m. | Break | |
| 9:45 a.m. 12:00 p.m. | Session 6: Prognosis in ALF/Role of Transplantation | Moderators: Ken Simpson, M.D., |
| | | David Koch, M.D. |
| | Prognostic Indices: Determining Outcomes | David Koch, M.D. |
| | Designing Clinical Trials in an Orphan Disease | Valerie Durkalski, Ph.D. |
| | Methacetin Breath Test and Other Tools | Robert Fontana, M.D. |
| | Outcomes of Transplantation: SRTR and ALFSG | Justin Parekh, M.D. |
| | Is ALF Going Away? An Epidemiologist's View | Baback Orandi, M.D. |
| 12:00 p.m. 1:00 p.m. | Lunch | |
| 1:00 p.m. 2:00 p.m. | Session 7: The Future of ALF: | Moderators: R. Todd Stravitz, M.D., |
| | Newer Modalities of Liver Support | Scott Nyberg, M.D. |
| | Liver support machines: Current status | Scott Nyberg, M.D. |
| | Stem cell recruitment for liver support | Russell Wesson, M.D. |
| | Final words | William M Lee, M.D. |
| | | |
| | | |
| | | |
| | | |
| | | |